Trials / Terminated
TerminatedNCT03978637
Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of itacitinib in participants with post-lung transplant bronchiolitis obliterans syndrome (BOS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Itacitinib | Itacitinib administered orally at the specified dose. |
Timeline
- Start date
- 2020-02-04
- Primary completion
- 2023-10-13
- Completion
- 2023-10-13
- First posted
- 2019-06-07
- Last updated
- 2025-10-20
- Results posted
- 2025-01-29
Locations
9 sites across 3 countries: United States, Belgium, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03978637. Inclusion in this directory is not an endorsement.